A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

NCT03152552 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

125

Enrollment

INDUSTRY

Sponsor class

Stopped This study terminated prematurely because of slow enrollment

Conditions

Diabetes Mellitus and Heart Failure

Interventions

DRUG: LIK066
DRUG: Placebo
DRUG: Empagliflozin

Sponsor

Novartis Pharmaceuticals